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Abstract: The aim of the present study is to investigate the effect and potential mechanism of 
action of 6-gingerol on alterations of vascular reactivity in the isolated aorta from diabetic rats. 
Male Wistar rats were divided into two experimental groups, control and diabetics. Diabetes was 
induced by a single intraperitoneal injection of streptozotocin (50 mg kg−1), and the rats were left 
for 10 weeks to develop vascular complications. The effect of in vitro incubation with 6-gingerol 
(0.3–3 µM) on the vasoconstrictor response of the isolated diabetic aortae to phenylephrine and 
the vasodilator response to acetylcholine was examined. Effect of 6-gingerol was also exam-
ined on aortae incubated with methylglyoxal as an advanced glycation end product (AGE). To 
investigate the mechanism of action of 6-gingerol, the nitric oxide synthase inhibitor Nω-nitro-
l-arginine methyl ester hydrochloride (100 µM), guanylate cyclase inhibitor methylene blue 
(5 µM), calcium-activated potassium channel blocker tetraethylammonium chloride (10 mM), 
and cyclooxygenase inhibitor indomethacin (5 µM) were added 30 minutes before assessing 
the direct vasorelaxant effect of 6-gingerol. Moreover, in vitro effects of 6-gingerol on NO 
release and the effect of 6-gingerol on AGE production were examined. Results showed that 
incubation of aortae with 6-gingerol (0.3–10 µM) alleviated the exaggerated vasoconstriction of 
diabetic aortae to phenylephrine in a concentration-dependent manner with no significant effect 
on the impaired relaxatory response to acetylcholine. Similar results were seen in the aortae 
exposed to methylglyoxal. In addition, 6-gingerol induced a direct vasodilation effect that was 
significantly inhibited by Nω-nitro-l-arginine methyl ester hydrochloride and methylene blue. 
Furthermore, 6-gingerol stimulated aortic NO generation but had no effect on AGE formation. 
In conclusion, 6-gingerol ameliorates enhanced vascular contraction in diabetic aortae, which 
may be partially attributed to its ability to increase the production of NO and stimulation of 
cyclic guanosine monophosphate.
Keywords: diabetes, 6-gingerol, vasorelaxant, nitric oxide, advanced glycation end products, 
vascular complications
Introduction
Diabetes mellitus (DM) is a common disease that affects almost 387 million people 
worldwide with a prevalence of 8.3% and an expected 205 million increase by 2035, 
according to the International Diabetes Federation.1 Despite significant improvements 
in controlling diabetes, vascular complications remain a major cause of morbidity and 
mortality in patients with DM.2 Macrovascular complications of DM include coronary 
artery disease,3 heart failure,4 and stroke.5 In addition, microvascular diseases of DM, 
including nephropathy6 and retinopathy,7 continue to cause morbidity and mortality. 
These vascular complications may be partially attributed to impairment of vasomotor 
function of smooth muscles.8,9
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Ginger rhizome (Zingiber officinale), commonly known 
as ginger, is utilized worldwide as a spice and a flavoring 
agent, with a long history of medicinal use for diseases, 
including arthritis, pain, sore throat, constipation, indiges-
tion, vomiting, dementia, fever, infectious diseases, and 
helminthiasis.10 Moreover, it is used in South Asia as a 
traditional medicine to treat cardiopathy and hypertension 
due to its vasodilator effect.11 Phytochemical reports showed 
that the main constituents of ginger are the gingerols, 
shogaols, zingerone, and paradol.12 6-Gingerol, one of the 
major elements of ginger, has been found to exhibit anti-
inflammatory,13 antihyperglycemic,14 antiangiogenic,15 and 
anticancer16 effects. In addition, antiplatelet aggregatory and 
vasorelaxatory effects of the constituents of ginger were 
reported by Liao et al.17 Hence, the current study is designed 
to investigate the effect and potential mechanism of action of 
6-gingerol on alterations of vascular reactivity in the isolated 
aorta from diabetic rats.
Materials and methods
Drugs and chemicals
6-Gingerol, Nω-nitro-l-arginine methyl ester hydrochloride 
(l-NAME), methylene blue (MB), tetraethylammonium chlo-
ride (TEA), indomethacin (INDO), aminoguanidine (AG), 
ribose, bovine serum albumin (BSA), acetylcholine (ACh), 
and phenylephrine (PE) were purchased from Sigma-Aldrich 
Co., St Louis, MO, USA, and 4-amino-5-methylamino-2′,7′-
difluorofluorescein (DAF-FM) diacetate was purchased from 
Molecular Probes, NY, USA. All chemicals were dissolved 
in ultrapure deionized water except for 6-gingerol, DAF-FM 
diacetate, and INDO, which were dissolved in dimethyl 
sulfoxide (DMSO). The final DMSO concentration did not 
exceed 0.1% that has no effect on vascular reactivity accord-
ing to our preliminary studies.
animals
Male Wistar rats (King Abdulaziz University, Saudi Arabia) 
weighing 120–140 g, aged 6 weeks, were housed in clear 
polypropylene cages (three to four rats per cage) and kept 
under constant environmental conditions with equal light–
dark cycle. The rats had free access to commercially available 
rodent pellet diet and purified water. All the experimental 
procedures were performed in accordance with Saudi Arabia 
Research Bioethics and Regulations, which are consistent 
with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health. The experi-
mental protocol was approved by the Unit of Biomedical 
Ethics Research Committee, King Abdulaziz University.
study protocol
The animals were randomly divided into two experi-
mental groups: control (C) and diabetic (D) groups (six 
to eight rats in each group). Diabetes was induced by a 
single intraperitoneal injection of streptozotocin (STZ, 
50 mg kg−1). Glucose levels in tail blood were determined 
using a glucose meter (ACCU-CHEK; Hoffman-La Roche 
Ltd., Basel, Switzerland) with noble metal electrode strips. 
Diabetes was confirmed by a stable hyperglycemia (blood 
glucose levels of 250–350 mg dL−1) after 2 weeks of STZ 
injection. The rats were left for an additional 8 weeks to 
develop vascular complications, based on the results of 
a recent work from our laboratories.18 The animals were 
then killed by decapitation with rodent guillotine, and the 
descending thoracic aorta was carefully excised and placed 
in cold Krebs–Henseleit buffer with the following composi-
tion (mM): NaCl 118.1, KCl 4.69, KH
2
PO
4
 1.2, NaHCO
3
 
25.0, glucose 11.7, MgSO
4
 0.5, and CaCl
2
 2.5. The aorta 
was then cleaned of fat and connective tissue and cut into 
three rings (∼3 mm length).
Vascular reactivity
Vascular reactivity of the isolated thoracic aortae was deter-
mined using the isolated artery techniques described in pre-
vious publications from our laboratories.19,20 Isolated aortae 
from the diabetic group were incubated with different con-
centrations of 6-gingerol (0.3–10 µM) for 30 minutes before 
assessing the vasoconstriction and vasodilation responses, 
whereas the isolated aortae from the control group were 
incubated in DMSO. For assessing the aortic contractile 
responsiveness, increases in tension due to cumulative addi-
tions of PE (1 nM to 10 µM) were recorded and expressed 
as milligram tension per milligram tissue wet weight. 
In order to study the vasodilator responsiveness of the 
aorta, the aortic rings were first precontracted with maximal 
concentrations of PE (10 µM). Cumulative concentrations 
of ACh (1 nM to µM) were then added to the organ bath 
and the response was recorded as percentage in relation to 
PE precontraction.
exposure of aortae to advanced glycation 
end products
Aortae isolated from the control animals were incubated 
with methylglyoxal (MG, 200 µM) for 60 minutes with or 
without different concentrations of 6-gingerol (0.3–3 µM) 
before studying the vasoconstriction response to PE and 
vasodilation response to ACh as described in the diabetic 
aortae experiments.
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Direct vasodilation effect of 6-gingerol
A set of experiments were carried out to investigate the direct 
vasorelaxant effect and mechanism of action of 6-gingerol. 
Cumulative concentrations of 6-gingerol (0.3–10 µM) 
were added to the organ bath containing the isolated aortae 
precontracted with PE (10 µM) and the decrease in tension 
was recorded.
In other sets of experiments, the nitric oxide synthase 
inhibitor l-NAME (100 µM), guanylate cyclase inhibitor MB 
(5 µM), calcium-activated potassium channel blocker TEA 
(10 mM), or cyclooxygenase inhibitor INDO (5 µM) was 
added 30 minutes before investigating the direct vasorelax-
ant effect of 6-gingerol as described earlier. The results of 
6-gingerol effects were expressed as log M.
ach-induced nO generation
Intracellular NO generation following ACh activation of 
the isolated aorta was investigated using the fluorescence probe 
DAF-FM diacetate as described in a previous work from our 
laboratories.18 Briefly, the isolated aortae were added to 
96-well black plates containing 110 µL saline and 2.5 µM 
DAF-FM with or without ACh or 6-gingerol (both at 1 mM) 
and incubated for 3 minutes at 37°C. Then, volumes of 90 µL 
were transferred to new wells, and the fluorescence intensity 
was measured at an excitation wavelength of 485 nm and 
an emission wavelength of 525 nm using a monochromator 
SpectraMax® M3 plate reader.
advanced glycation end product 
formation
The effect of 6-gingerol on advanced glycation end product 
(AGE) formation was assessed according to a previously 
reported method.21 Briefly, 10 mg mL−1 BSA was incu-
bated with 100 mM ribose in 100 mM phosphate-buffered 
saline (pH 7.4) containing 0.02% sodium azide at 37°C 
for 2 weeks in the absence or presence of 6-gingerol 
(1–1,000 µM) and AG (1 mM). The formation of fluorescent 
AGE was measured using a monochromator SpectraMax® 
M3 plate reader. The fluorescence intensity was measured 
at an excitation wavelength of 355 nm and an emission 
wavelength of 460 nm.
statistical analysis
Values are expressed as mean ± standard error of the mean. 
Statistical analysis was performed by the one- or two-way 
analysis of variance followed by Dunnett’s post hoc test 
using the statistical software Prism 5® (Graphpad Software, 
Inc., La Jolla, CA, USA).
Results
effect of 6-gingerol on vascular reactivity 
of diabetic aortae
Diabetic aortae showed exaggerated vasoconstriction in 
response to PE (10−9 to 10−5 M) compared with control aor-
tae. This enhancement of vasoconstriction was highly sig-
nificant (P0.001) at PE concentrations of 3×10−7 to 10−5 M 
(Figure 1A). Incubation with 6-gingerol (0.3–10 µM) for 
30 minutes alleviated the exaggerated vasoconstriction of 
diabetic aortae in a concentration-dependent manner. The 
inhibition of PE (10−5 M)-induced contraction was highly 
significant (P0.001) at 3 µM 6-gingerol and was signifi-
cant (P0.05) at 10 µM 6-gingerol (Figure 1A).
Diabetic aortae showed impaired vasodilation in response 
to ACh (10−9 to 10−5 M) compared with control aortae, 
which was highly significant (P0.001) at an ACh concen-
tration of 10−5 M. In contrast to the effects on PE-induced 
contraction, there was no significant effect of 6-gingerol 
(0.3–10 µM) on the relaxant effect of ACh (10−9 to 10−5 M; 
Figure 1B).
effect of 6-gingerol on vascular reactivity 
of aortae exposed to age
Incubation of diabetic aortae with MG produced exagger-
ated vasoconstriction in response to PE compared with 
control aortae (Figure 2), with an enhanced Emax and shift 
in pEC
50
. These differences in contraction were highly 
significant (P0.001) at 3×10−8 and 10−7 M PE concentra-
tions (Figure 2A). 6-Gingerol (3 µM) showed a significant 
(P0.05) alleviation of the exaggerated vasoconstriction in 
response to 10−8 and 10−5 M PE concentrations (Figure 2A). 
MG produced significant (P0.01) impairment in aortic 
vasodilation induced by ACh (3×10−6 and 10−5 M) in the 
diabetic aortae compared to that in the control aortae, while 
there was no significant effect of 0.3–10 µM 6-gingerol 
(Figure 2B).
Direct vasorelaxant effect of 6-gingerol
Addition of cumulative concentrations of 6-gingerol 
(3×10−5 to 10−3 M) to the organ bath resulted in a concentration-
 dependent vasodilation in the isolated diabetic aortae 
precontracted with PE that was statistically significant 
(P0.001) at 6-gingerol concentrations of 3×10−4 and 10−3 M. 
 Preincubation with l-NAME or MB (at 100 and 5 µM) 
for 30 minutes before the cumulative addition of 6-gingerol 
significantly inhibited the vasodilation effect of 6-gingerol 
(both at P0.001). In contrast, preincubation with TEA 
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(10 mM) or INDO (5 µM) did not significantly affect the 
vasodilation effect of 6-gingerol (Figure 3).
effect of 6-gingerol on nO generation
Incubation of the isolated diabetic aortae in media contain-
ing 6-gingerol (10−3 M) for 3 minutes produced significant 
NO generation in a dose-dependent manner (Figure 4A) 
and to a level similar to that induced by ACh (10−3 M; 
both at P0.05 compared with control; Figure 4B). High 
drug concentrations were used in these experiments in 
order to provide an adequate signal-to-noise ratio in the 
NO assay.
Figure 2 effect of 6-gingerol on the responsiveness of isolated aortae to Pe (A) and ach (B) following incubation with methylglyoxal (Mg) with increases in the formation 
of advanced glycation end products (ages).
Notes: Values shown are mean ± seM, n=8–10. **Significantly (P0.01) different from the respective control values. ***Significantly (P0.001) different from the respective 
control values. #Significantly (P0.05) different from the respective diabetic values.
Abbreviations: Pe, phenylephrine; ach, acetylcholine; seM, standard error of the mean; c, control.
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effect of 6-gingerol on age
Incubation of BSA with ribose increased AGE significantly 
(P0.001), as assessed by fluorimetry. This increased level 
of AGE was significantly (P0.001) ameliorated when 
incubated with AG (1 mM, as positive control), while there 
was no effect when incubated with different concentrations 
of 6-gingerol (Figure 5).
Discussion
To our knowledge, this is the first study to investigate the 
vasorelaxant mechanism of 6-gingerol, the main constituent of 
ginger, in diabetic aortae. The results show that the enhanced 
α-adrenergic responsiveness of aortic rings from diabetic ani-
mals was significantly attenuated by 6-gingerol. This inhibition 
was concentration dependent with a maximum effect at 3 µM. 
The observed alleviation of exaggerated vasoconstriction 
and the possible mechanism associated with diabetes may be 
explained based on the following results of the current study: 
1) 6-gingerol induced significant relaxation of PE-precontracted 
aortae, 2) the observed relaxation was significantly inhibited by 
the NO synthase inhibitor l-NAME and the guanylate cyclase 
inhibitor MB, and 3) 6-gingerol stimulated NO generation from 
the isolated aortae. These findings provide convincing evidence 
that 6-gingerol offsets the exaggerated vasoconstriction in 
diabetic aortae through NO-dependent mechanism. The use of 
6-gingerol as a complementary medicine in diabetes may help 
to ameliorate the associated vascular complications.
Increased vascular responsiveness to contractile agents in 
STZ-diabetic rats has been reported in most of the previous 
studies,22–24 which strongly supports the use of the diabetic 
model in the current study with regard to vascular abnormalities. 
Alternatively, some studies reported unchanged25 or reduced26 
vascular response to α-adrenergic agonists, which could 
possibly be explained by the use of low PE concentrations25 
or the nonspecific adrenergic agonist noradrenaline.26
In addition, attenuated relaxation responses to ACh 
were observed in the current study in STZ-diabetic aorta, in 
Figure 3 effect of the nitric oxide synthase inhibitor nω-nitro-l-arginine methyl 
ester hydrochloride (l-naMe, 100 µM), guanylate cyclase inhibitor methylene blue 
(MB, 5 µM), calcium-activated potassium channel blocker tetraethylammonium 
chloride (Tea, 10 mM), and cyclooxygenase inhibitor indomethacin (inDO, 5 µM) 
on the direct vasorelaxant effect of 6-gingerol, expressed as log M.
Notes: ***Significantly (P0.001) different from the respective control values. 
Points show mean ± seM of n=5–8 tissues.
Abbreviation: seM, standard error of the mean.
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agreement with the findings of Orie et al.27 In STZ-induced 
DM, basal levels of NO production and expression of eNOS 
are reduced in diabetic arteries.28 In the present study, the 
exaggerated vasoconstriction seen in diabetic aortae was 
significantly attenuated with short-term in vitro incubation 
with 6-gingerol in a concentration-dependent manner, while 
the impaired relaxation was not affected.
Because of its pivotal role in the development of cardio-
vascular complications,29 the effect of an AGE metabolite 
(MG) on vascular contractility and the possible effect of 
6-gingerol were investigated. The current study shows that 
the aortic rings incubated with MG showed an enhanced 
contractile response to PE similar to diabetic aortae, and 
this enhanced effect was significantly ameliorated with 
6-gingerol. This is in accordance with the reported inhibi-
tion of NO availability by AGE in human endothelial cells.30 
In contrast, the relaxation response to ACh was significantly 
attenuated when the aortic rings were incubated with MG. This 
is in accordance with the results of Vlassara et al,31 who showed 
that administration of AGE-modified albumin to nondiabetic 
rats or rabbits markedly impairs vasodilatory responses to 
ACh. In the present study, incubation with 6-gingerol signifi-
cantly alleviated the exaggerated vasoconstriction in the aortae 
exposed to MG, but did not affect the impaired relaxation.
The mechanism(s) by which 6-gingerol alleviates vaso-
constriction of diabetic aortae could be mediated by direct 
vasodilation through NO generation and stimulation of GC. 
In the present study, 6-gingerol induced significant relaxation 
of PE-precontracted aortae. This is in agreement with the 
reported antihypertensive effect of ginger aqueous extract 
and its phenolic constituents in rats.32 The observed vasodila-
tion seems to be through stimulating NO generation from the 
vasculature as it was significantly inhibited by the NOS inhibi-
tor and the GC inhibitor, while not affected by the calcium-
activated potassium channel blocker or the cyclooxygenase 
inhibitor INDO. In support of this, we found that 6-gingerol 
stimulated similar amounts of NO generation to those by ACh. 
In contrast, incubation with 6-gingerol did not affect AGE 
formation. This suggests that the observed alleviation of exag-
gerated vasoconstriction by 6-gingerol due to MG incubation 
is through inhibiting the effects of AGE on the blood vessels 
rather than affecting AGE formation. This is consistent with 
the reported decrease in the soluble receptor for AGE induced 
by 6-gingerol in doxorubicin-treated rats.33
Conclusion
The current study showed that 6-gingerol ameliorates 
enhanced vascular contraction in diabetic aortae, which may 
be partially attributed to the vasodilation effect of 6-gingerol 
through stimulation of aortic NO generation.
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